CHOICE KERGUELEN 2 : Consequences of Longterm Confinement on Immunity in the Sub-Antarctic Islands : Follow-up of Volunteers on the Kerguelen Islands

Consequences of Longterm Confinement on Immunity in the Sub-Antarctic Islands : Follow-up of Volunteers on the Kerguelen Islands

Living for long periods in extreme environments-like Antarctic research stations or space missions-can have a significant impact on human health, especially on the immune system. Scientists have observed that people in such isolated conditions often experience more infections and a reactivation of viruses that usually stay dormant in the body, such as Herpes viruses. These changes affect both parts of the immune system: the rapid-response "innate" system and the slower, more specific "adaptive" system.

These immune disruptions may be caused by multiple stressors: ongoing psychological stress, disturbed sleep and light cycles (circadian rhythm disruption), and the challenges of living in confined, isolated, and extreme environments. While space missions and Antarctic overwintering programs have provided some insight into these issues, scientists still lack a detailed understanding of how the immune system adapts-or fails to adapt-over time in such conditions.

To help fill this gap, the CHOICE Kerguelen 2 study will follow a group of healthy young adults who will spend one year (from November 2025 to November 2026) in Port-aux-Français, a remote French research station on the Kerguelen Islands in the sub-Antarctic. These volunteers are participating in a civic service program and will be living in a highly isolated environment for the duration of their mission. The CHOICE Kerguelen study is conducted in collaboration with the French Polar Institute (IPEV).

The goal of the study is to collect and store a broad range of biological samples-including blood, saliva, stool, urine, and hair-from these volunteers at four time points during the time of their confinement on the Kerguelent Islands: tevery three months during their stay. These samples will be than analyzed to characterize the immune profiles and intestinal microbiota of the subjects assess eventual viral reactivations and stress biological markers. These analyses will allow to better understand how the immune system reacts to prolonged isolation, and to identify immune profiles that may develop under prolonged stress and limited social contact.

The long-term aim of this project is not only to improve our understanding of human immunity in extreme environments, but also to inform medical research for people living with chronic illness. By studying healthy individuals placed in physically and mentally challenging environments, scientists can better understand how stress and isolation may weaken immune defenses. The findings may one day help design new approaches to support immune health in vulnerable populations.

Study Overview

• Status: Recruiting
• Conditions: Human Health in Extreme Conditions
• Intervention / Treatment: Other: blood ponction; Other: urines collection; Other: hair collection; Other: saliva collection; Other: stools collection

• Study Type: Observational
• Enrollment (Estimated): 9

Contacts and Locations

• Study Contact: Name: Anthéa LOIEZ; Phone Number: +33 02 41 35 36 37; Email: DRCI-Promotion-Interne@chu-angers.fr
• Study Contact Backup: Name: Charline MIOT, MD; Phone Number: +33 02 41 35 36 37; Email: chmiot@chu-angers.fr

Study Locations

• French Southern and Antarctic Lands
  • Terres Australes Et Antarctiques Françaises
    • Port-aux-Français, Terres Australes Et Antarctiques Françaises, French Southern and Antarctic Lands
      • Recruiting
      • Hôpital SAMUKER, Port-aux-français/ Archipel KERGUELEN /Terres Australes et Antarctiques Françaises
      • Contact: Marine MEYERBER, MD; Phone Number: +5 02 62 00 40 33; Email: medecin@ker-taaf.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Participant included in the CELREMED research project of the University Hospital of Angers on helathy volunteers in the context of CHOICE Kerguelen 1 protocol

Description

Inclusion Criteria :

• healthy people aged > 18 years
• Participant affiliated with or benefiting from a social security system
• Participant has signed informed consent
• Participant staying as an overwintering member at Kerguelen from November 2025 to November 2026
• Participant included in the CELREMED research project of the University Hospital of Angers on helathy volunteers in the context of CHOICE Kerguelen 1 protocol

Exclusion Criteria:

• age < 18 years
• Pregnant, breastfeeding, or postpartum woman
• immunocompromised people (primary immunodeficiency, HIV infection or immunosupressive treatment)
• Person refusing to participate in the study
• Person with a history of autoimmune disease - -Person deprived of liberty by judicial or administrative decision
• Person undergoing involuntary psychiatric treatment
• Person subject to a legal protection measure

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
HD (healthy donors)	Other: blood ponction; blood ponction; Other: urines collection; urines collection; Other: hair collection; hair collection; Other: saliva collection; saliva collection; Other: stools collection; stools collection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
lymphocytes subsets during overwintering on the Kerguelen Islands	lymphocytes subsets by flow cytometry	At inclusion (3 months after the beginning of overwintering)
lymphocytes subsets during overwintering on the Kerguelen Islands	lymphocytes subsets by flow cytometry	At 3 months (6 months after the beginning of overwintering )
lymphocytes subsets during overwintering on the Kerguelen Islands	lymphocytes subsets by flow cytometry	At 6 months (9 months after the beginning of overwintering )
lymphocytes subsets during overwintering on the Kerguelen Islands	lymphocytes subsets by flow cytometry	At 9 months (12 months after the beginning of overwintering )
RNAsep during overwintering on the Kerguelen Islands	RNAseq	At inclusion (3 months after the beginning of overwintering )
RNAsep during overwintering on the Kerguelen Islands	RNAseq	At 3 months (6 months after the beginning of overwintering )
RNAsep during overwintering on the Kerguelen Islands	RNAseq	At 6 months (9 months after the beginning of overwintering )
RNAsep during overwintering on the Kerguelen Islands	RNAseq	At 9 months (12 months after the beginning of overwintering )
plasmatic cytokines during overwintering on the Kerguelen Islands	plasmatic cytokines by Bioplex	At inclusion (3 months after the beginning of overwintering )
plasmatic cytokines during overwintering on the Kerguelen Islands	plasmatic cytokines by Bioplex	At 3 months (6 months after the beginning of overwintering )
plasmatic cytokines during overwintering on the Kerguelen Islands	plasmatic cytokines by Bioplex	At 6 months (9 months after the beginning of overwintering )
plasmatic cytokines during overwintering on the Kerguelen Islands	plasmatic cytokines by Bioplex	At 9 months (12 months after the beginning of overwintering )
fecal microbiota	fecal microbiota by bacterial sequencing	At inclusion (3 months after the beginning of overwintering )
fecal microbiota	fecal microbiota by bacterial sequencing	At 3 months (6 months after the beginning of overwintering )
fecal microbiota	fecal microbiota by bacterial sequencing	At 6 months (9 months after the beginning of overwintering )
fecal microbiota	fecal microbiota by bacterial sequencing	At 9 months (12 months after the beginning of overwintering )
hormonal stress markers during overwintering on the Kerguelen Islands	hormonal stress markers assessment in blood/urinary/hair by Elisa and nephelemetry	At inclusion (3 months after the beginning of overwintering )
hormonal stress markers during overwintering on the Kerguelen Islands	hormonal stress markers assessment in blood/urinary/hair by Elisa and nephelemetry	At 3 months (6 months after the beginning of overwintering )
hormonal stress markers during overwintering on the Kerguelen Islands	hormonal stress markers assessment in blood/urinary/hair by Elisa and nephelemetry	At 6 months (9 months after the beginning of overwintering )
hormonal stress markers during overwintering on the Kerguelen Islands	hormonal stress markers assessment in blood/urinary/hair by Elisa and nephelemetry	At 9 months (12 months after the beginning of overwintering )
stress profile during overwintering on the Kerguelen Islands	psychological stress by CST test form	At inclusion (3 months after the beginning of overwintering )
stress profile during overwintering on the Kerguelen Islands	psychological stress by CST test form	At 3 months (6 months after the beginning of overwintering )
stress profile during overwintering on the Kerguelen Islands	psychological stress by CST test form	At 6 months (9 months after the beginning of overwintering )
stress profile during overwintering on the Kerguelen Islands	psychological stress by CST test form	At 9 months (12 months after the beginning of overwintering )

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
EBV viral reactivations during overwintering on the Kerguelen Islands	EBV in blood and saliva by quantitative PCR	At inclusion (3 months after the beginning of overwintering )
EBV viral reactivations during overwintering on the Kerguelen Islands	EBV in blood and saliva by quantitative PCR	At 3 months (6 months after the beginning of overwintering )
EBV viral reactivations during overwintering on the Kerguelen Islands	EBV in blood and saliva by quantitative PCR	At 6 months (9 months after the beginning of overwintering )
EBV viral reactivations during overwintering on the Kerguelen Islands	EBV in blood and saliva by quantitative PCR	At 9 months (12 months after the beginning of overwintering )
CMV viral reactivations during overwintering on the Kerguelen Islands	CMV in blood and saliva by quantitative PCR	At inclusion (3 months after the beginning of overwintering )
CMV viral reactivations during overwintering on the Kerguelen Islands	CMV in blood and saliva by quantitative PCR	At 3 months (6 months after the beginning of overwintering )
CMV viral reactivations during overwintering on the Kerguelen Islands	CMV in blood and saliva by quantitative PCR	At 6 months (9 months after the beginning of overwintering )
CMV viral reactivations during overwintering on the Kerguelen Islands	CMV in blood and saliva by quantitative PCR	At 9 months (12 months after the beginning of overwintering )
HSV viral reactivations during overwintering on the Kerguelen Islands	HSV in blood and saliva by quantitative PCR	At inclusion (3 months after the beginning of overwintering )
HSV viral reactivations during overwintering on the Kerguelen Islands	HSV in blood and saliva by quantitative PCR	At 3 months (6 months after the beginning of overwintering )
HSV viral reactivations during overwintering on the Kerguelen Islands	HSV in blood and saliva by quantitative PCR	At 6 months (9 months after the beginning of overwintering )
HSV viral reactivations during overwintering on the Kerguelen Islands	HSV in blood and saliva by quantitative PCR	At 9 months (12 months after the beginning of overwintering )
TTV viral reactivations during overwintering on the Kerguelen Islands	TTV viral loads in blood and saliva by quantitative PCR	At inclusion (3 months after the beginning of overwintering )
TTV viral reactivations during overwintering on the Kerguelen Islands	TTV viral loads in blood and saliva by quantitative PCR	At 3 months (6 months after the beginning of overwintering )
TTV viral reactivations during overwintering on the Kerguelen Islands	TTV viral loads in blood and saliva by quantitative PCR	At 6 months (9 months after the beginning of overwintering )
TTV viral reactivations during overwintering on the Kerguelen Islands	TTV viral loads in blood and saliva by quantitative PCR	At 9 months (12 months after the beginning of overwintering )

Collaborators and Investigators

• Sponsor: University Hospital, Angers
• Collaborators: Institut Polaire Français Paul Emile Victor
• Investigators: Principal Investigator: Charline MIOT, MD, University Hospital, Angers

Study record dates

Study Major Dates

• Study Start (Actual): December 20, 2025
• Primary Completion (Estimated): January 31, 2026
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: November 27, 2025
• First Submitted That Met QC Criteria: November 27, 2025
• First Posted (Estimated): December 10, 2025

Study Record Updates

• Last Update Posted (Actual): December 30, 2025
• Last Update Submitted That Met QC Criteria: December 23, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Other Study ID Numbers: 49RC25_0439; 2025-A02538-41 (Other Identifier: ANSM)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Data will be shared upon reasonable request. Only de-identified data will be shared. Any data collected during the study may be shared. The protocol will be shared initially. Other documents may be shared at a later date upon request (e.g., the CRF to allow a collaborator to select the data they wish to access). The recipients of the data will be researchers. The data will be available for any purpose deemed relevant by the study investigator, based on a protocol provided by the requester, after verification of the obtaining of regulatory approvals, including the favorable opinion of an ethics committee.
• IPD Sharing Time Frame: The data will be shared after signing a negotiated data transfer agreement ( data access agreement), for the duration specified in the agreement.
• IPD Sharing Access Criteria: The data will be made available via secure transfer (sharing platform approved by the university hospital: BlueFiles or Oodrive).
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No